FORRESTER
Forrester (Nasdaq: FORR) today announced the full conference agenda for Technology & Innovation Summit EMEA, held in London and digitally, October 9–11, 2024. While the potential of generative AI (genAI) to enhance efficiency and innovation is evident, tech leaders must strike the right balance, leveraging emerging technologies like automation and genAI to fuel innovation while also making sure to avoid stifling it. They need to understand where AI can make the most significant impact and identify the necessary resources for effective implementation.
At this year’s Technology & Innovation Summit EMEA, technology, data and analytics, and cybersecurity leaders will have insight into new research and learn best practices to achieve high-performance IT, understand the ethical, safe, and secure ways to take advantage of new technologies that are fundamental to building trust with their customers, and assess how to use AI as a catalyst for innovation and change.
Noteworthy keynotes and sessions include:
- Generative AI As A Forcing Factor For Change. In this keynote, technology leaders will learn how to maximise their investment in genAI to scale beyond a single use case.
- Unleash Your Potential With High-Performance IT. This keynote will cover how to align and adapt to changing business dynamics with high-performance IT.
- Embrace Trust, Adaptivity, And Alignment for AI Success. In this keynote, leaders will understand how to address the AI bottleneck by breaking down operational and data silos.
- A Fun (Yes, Really) Crash Course In EU AI Act Compliance. This session will reveal which initiatives and capabilities to prioritise and outline a dedicated roadmap to help tech leaders prepare for the impending EU AI Act.
- Staying Resilient In A Fluid Technology And Threat Landscape. In this keynote, cybersecurity leaders will explore how to approach AI practically, balancing risk and opportunity.
- AI, Low-Code, And The End Of Software Development As We Know It. This keynote will discuss the impact of genAI on the software development lifecycle and explore the emergence of application generation platforms infused with both predictive and generative AI.
“Tech, data, and security leaders in Europe are under tremendous pressure to deliver on AI investments,” said Pascal Matzke, Forrester VP and research director and T&I EMEA event host. “At Technology & Innovation EMEA, leaders will learn how to overcome common obstacles associated with the adoption of genAI and how leaders can effectively steer, align, and motivate their business to successfully scale their genAI initiatives.”
In-person attendees will experience facilitated discussions, consulting workshops, and special programmes, including the Women’s Leadership Programme; the Executive Leadership Exchange, an exclusive programme targeted at C-level leaders; and several diversity and inclusion sessions. Digital attendees will have access to all conference sessions and sponsors via the event platform.
Resources:
- Register to attend Forrester’s Technology & Innovation Summit EMEA 2024.
- View the full agenda and speakers for Technology & Innovation Summit EMEA 2024.
- Follow @Forrester and #ForrTech for updates.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the centre of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903845085/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 05:25:00 CET | Press release
FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 04:31:00 CET | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 03:00:00 CET | Press release
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom